CleveXel Pharma and Dynamix to develop oral treatment for RA

25 November 2013

France-based pharma company CleveXel Pharma has entered into a partnering agreement with venture-backed Israeli biopharmaceutical company Dynamix Pharmaceuticals to cover the development of a dual mechanism Syk/ Janus kinase (JAK) molecule in rheumatoid arthritis (RA).

Dynamix’ lead development program, the orally active SYK/JAK product, reflects efforts over the last decade to provide an oral treatment for RA with the desired efficacy and safety profile. Current treatments are mainly only injectable so the joint aim of the collaboration is to bring the RA project to a clinical proof of concept stage. Preclinical development is planned for early 2014 and the first clinical trial is expected to start in 2015.

CleveXel chief executive Christian Bloy commented: “For CleveXel, the partnership will innovate in inflammatory disease, potentially also in oncology. JAK3 and SYK represent new targets that are extremely interesting in order to develop an orally administered product. CleveXel Pharma is very happy to be part of this leading project with Dynamix.”

Joins other JAK inhibitors in RA market

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK